Showing results (101-110 of 109) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|September 8, 2019
Cytotoxic effects of 4'-hydroxychalcone on human neuroblastoma cells (SH-SY5Y)Stephane Janaina de Moura Escobar, Martin Simone, Nathan Martin, et al.Data in Brief|March 3, 2025
New coastal records in northern Brittany (Plouescat, NW France): Sedimentological, palynological and paleogenomic data over the last 7.3 ka BPOphélie David, Muriel Vidal, Aneta Gorczyńska, et al.British Journal of Haematology|July 16, 2025
Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myelomaNathan Martin, Ethan Thompson, Nicholas Stong, et al.International Journal of Molecular Sciences|January 2, 2019
NFκB Inhibition Mitigates Serum Amyloid A-Induced Pro-Atherogenic Responses in Endothelial Cells and Leukocyte Adhesion and Adverse Changes to Endothelium Function in Isolated AortaAbigail Vallejo, Belal Chami, Joanne M Dennis, et al.Hemasphere|July 3, 2026
Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myelomaBruno Paiva, Irene Manrique, Ethan Thompson, et al.Blood Cancer Discovery|July 24, 2023
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene VicleucelBruno Paiva, Irene Manrique, Julie Rytlewski, et al.Cancer Immunology Research|January 21, 2026
Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy bb21217 for relapsed and refractory multiple myeloma: results from the phase 1 CRB-402 studyMelissa Alsina, Nina Shah, Sundar Jagannath, et al.Nature Medicine|August 17, 2023
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trialYi Lin, Noopur S Raje, Jesús G Berdeja, et al.Leukemia|September 19, 2025
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myelomaJulia Frede, Julia C Poller, Kayleen Shi, et al.Pageof 11